A new method to remove HIV-infected cells from the body
Official title: A new strategy to eliminate HIV-1-infected cells by unlocking the Env trimer
Funded at Henry M. Jackson Fdn for the Adv Mil/med · NIH-10900611 · Data updated 2026-11-12
This study is working on new antibodies that can help your body fight HIV by targeting and destroying infected cells, with the hope of creating better treatments for people living with the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | August 7, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $699,744 |
| NIH project number | 5R01AI174908-02 |
| Project ID | NIH-10900611 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV-1 who have not achieved viral suppression with current therapies.
✕Less likely to help
Patients who are not infected with HIV-1 or those who have advanced AIDS may not benefit from this research.
What this research studies
This research focuses on developing engineered antibodies that target specific parts of the HIV virus to help eliminate infected cells. By creating antibodies that can effectively recognize and attack these cells, the study aims to enhance the body's immune response against HIV. The approach involves using therapeutic antibodies that are designed to work better in the presence of HIV-infected plasma, potentially leading to more effective treatments for individuals living with HIV. The research builds on previous successes in antibody development and aims to create a new class of treatments that could significantly reduce the viral reservoir in patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV, potentially allowing for the elimination of the virus from the body.
How similar studies have gone: Other research has shown promise in using engineered antibodies for HIV treatment, indicating that this approach has potential based on previous successes.
Where this research is happening
-
Henry M. Jackson Fdn for the Adv Mil/med
Bethesda, United States Active
Researchers
- Principal investigator: Pazgier, Marzena Elzbieta — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Pazgier, Marzena Elzbieta
Related research
Other NIH-funded projects on the same topics.
-
Cooperation partners of SETBP1 in AML development
This grant explores how SETBP1 and AF9 (MLLT3) work together to drive acute myeloid leukemia and whether targeting related epigenetic regulators could help treat aggressive CK-AML.
-
U.S. Military HIV Research Program Clinical Trials Unit expansion
A nationwide network of clinical trial sites is being expanded to test HIV prevention and treatment approaches through DAIDS-supported trials.
-
Novel protein biomarkers of chronic pain in adults using a pain registry biobank
A study in adults with chronic pain will look for new protein biomarkers in blood samples to understand better why pain persists and how to improve treatment.
-
Tailored antibody cures for HIV using AI and vaccines
A study to design personalized antibody-based strategies to achieve HIV remission, using lab experiments and computer models to tailor vaccines or antibody treatments to individuals or small groups.
-
Understanding how antibody protection works using 3D protein structures
Researchers will build a 3D-based method to see which viral features relate to prevention by antibodies, using data from people in HIV vaccine and monoclonal antibody trials.
-
Military HIV Clinical Network
This program runs HIV and TB prevention and treatment clinical studies for adults in military-associated and high-HIV-burden communities.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.